Updates are available Correction dated 2022-09-05
Click to view Correction: https://doi.org/10.1038/s41380-022-01754-w
-
Authors
Bekhbat, Mandakh
Li, Zhihao
Mehta, Namrataa D.
Treadway, Michael T. http://orcid.org/0000-0002-5913-114X
Lucido, Michael J.
Woolwine, Bobbi J.
Haroon, Ebrahim
Miller, Andrew H. http://orcid.org/0000-0001-8260-7997
Felger, Jennifer C. http://orcid.org/0000-0003-4354-2267
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH109637, R61MH121625, R21MH121891, R01MH128872, F32MH119750, F31MH119745, R01MH108605, R21MH119622, R01MH107033, R01MH112076)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 9 December 2021
Revised: 6 July 2022
Accepted: 19 July 2022
First Online: 4 August 2022
Change Date: 5 September 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41380-022-01754-w
Competing interests
: In the past 3 years, JCF has consulted for Otsuka and Health BioConsulting on topics unrelated to this work. MTT has served as a paid consultant to Blackthorn Therapeutics. MTT is a co-inventor of the EEfRT, which is discussed in this manuscript. Emory University and Vanderbilt University licensed this software to BlackThorn Therapeutics. Under the IP Policies of both universities, MTT receives licensing fees and royalties from BlackThorn Therapeutics. Additionally, MTT has a paid consulting relationship with BlackThorn. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies, and no funding from these entities was used to support the current work. The remaining authors declare no competing interests. All views expressed are solely those of the authors.
